Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chindex Announces Higher $23/Share Takeover Offer

publication date: Apr 14, 2014
Chindex, the US-based operator of China hospitals and clinics, received a new takeover offer of $23 per share from an undisclosed entity. The offer is an 18% improvement on the $19.50 bid, made in February, from a group comprised of Fosun Pharma, TPG (a US private equity group) and Roberta Lipson, CEO of Chindex. A definitive agreement has been negotiated with the entity behind the latest offer, which is all-cash and not subject to any financing contingencies. More details....

Stock Symbols: (NSDQ: CHDX) (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital